ARGiNAUT Study: Potential New Pathway to Treating IPF
Trial Objectives
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease where scar tissue builds up in the lungs, making it harder to breathe.Researchers are evaluating a new medication called AZD8965 that may block the formation of scar tissue in the lungs, helping slow the progression of IPF and other related conditions. The study will help determine if the medication is effective and safe for people with IPF and related conditions.
Study participants will be assigned to receive one of three different doses of AZD8965 or a placebo (a medication with no active ingredient). During clinic visits volunteers will have vital signs recorded, provide blood and urine samples, and receive tests that record the body’s response to treatment, including spirometry and electrocardiograms (ECGs).
Who Can Participate
Adults 40 and older with a diagnosis of IPF, who either are not currently taking anti-fibrotic medication or who have been on their current medication for at least 12 weeks.
Age: 40+ Gender: Any
Estimated Time Commitment
Approximately 31 weeks
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
AstraZeneca
Principal Investigators
Michael P. Mohning, MD